Literature DB >> 8065165

Cytotoxic effect of extracellular ATP on L1210 leukemic cells and normal hemopoietic stem cells.

Y Hatta1, S Aizawa, T Itoh, M Baba, T Horie.   

Abstract

The cytotoxic effect of extracellular adenosine triphosphate (ATP) was examined on normal murine hemopoietic stem cells and a representative leukemic cell line (L1210). After L1210 cells were incubated with 4 mM ATP for 3 h, 3H-thymidine incorporation was almost completely inhibited. The number of viable L1210 cells was also significantly decreased and L1210 colony formation was suppressed to approximately 30% of the control level after treatment. The CFU-GM survival rate was reduced to 70%, however, CFU-S and marrow nucleated cell numbers were not changed after the same treatment with ATP. All mice that were injected with the untreated mixture of normal marrow cells (3.3 x 10(4)) and L1210 cells (3.3 x 10(3)) died of leukemia within 18 days. On the contrary, 85% of the recipients given ATP-treated grafts survived more than 70 days. These findings indicate that ATP extra vivo treatment is useful for purging the residual leukemic cells in autologous bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8065165     DOI: 10.1016/0145-2126(94)90046-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

Review 1.  Purinergic signaling in embryonic and stem cell development.

Authors:  Geoffrey Burnstock; Henning Ulrich
Journal:  Cell Mol Life Sci       Date:  2011-01-08       Impact factor: 9.261

Review 2.  Adenosine triphosphate: established and potential clinical applications.

Authors:  H J Agteresch; P C Dagnelie; J W van den Berg; J H Wilson
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 3.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.